Form: 8-K

Current report filing

May 9, 2005


SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported): May 6, 2005

 


 

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 


 

Virginia   001-13467   56-1641133

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

601 Biotech Drive

Richmond, Virginia 23235

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (804) 648-3820

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

(a) On May 6, 2005, Commonwealth Biotechnologies, Inc. announced the release of its financial results for the first quarter of 2005. Such results will be released on or about May 15, 2005 on Form 10-QSB. A copy of the press release announcing the results is attached as an exhibit hereto.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(a) Financial statements of businesses acquired.

 

Not Applicable.

 

(b) Pro forma financial information.

 

Not Applicable.

 

(c) Exhibits.

 

  99.1     Press release, dated May 6, 2005, relating to the announcement of financial results for the first quarter of 2005.

 

2


Pursuant to the requirement of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

COMMONWEALTH BIOTECHNOLOGIES, INC.
By:  

/s/ Robert B. Harris, Ph.D.


    Robert B. Harris, Ph.D.
    President and Chief Executive Officer

 

Dated: May 9, 2005

 

3


EXHIBIT INDEX

 

Number

  

Description of Exhibit


99.1    Press release, dated May 6, 2005, relating to the announcement of financial results for the first quarter of 2005.

 

4